Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEN2293 topical proof-of-concept study in mild to moderate atopic dermatitis
NL-OMON51714Phase 2Completed
- Sponsor
- BenevolentAI
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing BEN2293 with Matching placebo (2 arms). Primary endpoints: Adverse events, Local tolerance assessments and 3 more. Started Aug 2022; status: completed.
02
Drugs
BEN-2293
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON51714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51714.